KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Dividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Resmed (RMD) Share-based Compensation (2016 - 2025)

Historic Share-based Compensation for Resmed (RMD) over the last 17 years, with Q4 2025 value amounting to $28.9 million.

  • Resmed's Share-based Compensation rose 2785.19% to $28.9 million in Q4 2025 from the same period last year, while for Dec 2025 it was $99.0 million, marking a year-over-year increase of 1695.15%. This contributed to the annual value of $91.7 million for FY2025, which is 1431.33% up from last year.
  • Latest data reveals that Resmed reported Share-based Compensation of $28.9 million as of Q4 2025, which was up 2785.19% from $21.2 million recorded in Q3 2025.
  • Resmed's 5-year Share-based Compensation high stood at $28.9 million for Q4 2025, and its period low was $15.6 million during Q1 2021.
  • Its 5-year average for Share-based Compensation is $19.5 million, with a median of $19.2 million in 2023.
  • As far as peak fluctuations go, Resmed's Share-based Compensation tumbled by 534.48% in 2022, and later soared by 2785.19% in 2025.
  • Over the past 5 years, Resmed's Share-based Compensation (Quarter) stood at $16.1 million in 2021, then increased by 2.25% to $16.5 million in 2022, then increased by 20.51% to $19.8 million in 2023, then grew by 14.08% to $22.6 million in 2024, then increased by 27.85% to $28.9 million in 2025.
  • Its Share-based Compensation stands at $28.9 million for Q4 2025, versus $21.2 million for Q3 2025 and $24.8 million for Q2 2025.